COOLinactive

POLARITYTE, INC.

Healthcare·Neurology·Phase 3
NeurologyDermatology

POLARITYTE, INC. (COOL): 1 pipeline candidate · ~4 mo cash runway · 2 clinical trials. Updated within the last hour.

5.6/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.2

4.2 months

Financial Health9.3

D/E 0.45 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for POLARITYTE, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$6.4M

Quarterly Burn

$5.1M

Runway

4.2 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2026
Today~7 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
skintePhase 3
2 clinical trials

Frequently asked questions

How many drug candidates are in POLARITYTE, INC.'s pipeline?

POLARITYTE, INC. (COOL) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is POLARITYTE, INC.'s lead drug candidate?

POLARITYTE, INC.'s most advanced tracked candidate is skinte (Phase 3) for DFU; Diabetic Foot.

What is POLARITYTE, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, POLARITYTE, INC. has approximately 4.2 months of cash runway.

Get the full picture on POLARITYTE, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.